US authorises 23andMe's test for cancer risk

7 March 2018 - Deborah Wilkes

Archived

The US Food and Drug Administration (FDA) has authorised 23andMe's direct-to-consumer (DTC) genetic test for the risk of breast, ovarian and prostate cancer.

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: